Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge - In Suck Choi, Ie Byung Park, Kiyoung Lee, Tae Hoon
Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB | SpringerLink
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) - ScienceDirect
There's just been AKI. So what do we do with the ACEi/ARB? — NephJC
Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? - ScienceDirect
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension - Thomas T van Sloten, Patrick C Souverein, Coen DA Stehouwer, Johanna HM Driessen, 2022
Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension? | SpringerLink
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research
Cureus | Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Incidence of Lung Cancer: A Retrospective Study | Article
Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19 | SpringerLink
Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost‐effectiveness analysis - Wu - 2018 - Journal of Diabetes Investigation - Wiley Online Library
Therapeutics Initiative | How do you prescribe ACEIs and ARBs for hypertension?
ACE (Angiotensin-Converting Enzyme) Inhibitors/Angiotensin Receptor Blockers Are Associated With Lower Colorectal Cancer Risk | Hypertension
Frontiers | The effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in critically ill patients with acute kidney injury: An observational study using the MIMIC database
Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19 - The Centre for Evidence-Based Medicine
SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy - eBioMedicine
RACGP - ACEIs for cardiovascular risk reduction – have we taken our eye off the ball?
COVID-19 and Use of Drugs Targeting the Renin-Angiotensin-System - American College of Cardiology
Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome | Journal of Translational Medicine | Full Text
Which Inhibitor of the Renin–Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? | Circulation
JCM | Free Full-Text | Angiotensin Converting Enzyme Inhibitors versus Receptor Blockers in Patients with Ventricular Tachyarrhythmias
ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients - Zhao - 2021 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Cross-Reactivity of ACE Inhibitor–Induced Angioedema with ARBs
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension – An Update of the 2007 Report | Effective Health Care (EHC) Program
